依帕司他治疗早期2型糖尿病肾病临床观察

Clinical Observation of Epalrestat in the Treatment of Early Type 2 Diabetes Nephropathy

目的探讨依帕司他治疗早期2型糖尿病肾病的临床疗效。方法选取医院2021年5月至2023年5月收治的糖尿病肾病患者64例,随机分为对照组和观察组,各32例。两组患者均予常规综合治疗,观察组患者加服依帕司他片,两组均持续治疗12周。结果与对照组比较,观察组患者治疗后的糖化血红蛋白、空腹血糖、餐后2小时血糖水平均显著降低(P<0.05),尿量显著增加,尿蛋白和尿素氮水平均显著降低(P<0.05)。两组不良反应发生率无显著差异(P>0.05)。结论依帕司他治疗早期2型糖尿病肾病,能提高血糖控制效果,促进患者的肾功能恢复。

Objective To investigate the clinical efficacy of epalrestat in the treatment of early type 2 diabetes nephropathy.Methods A total of 64 patients with diabetes nephropathy admitted to the hospital from May 2021 to May 2023 were selected and randomly divided into the control group and the observation group,with 32 cases in each group.Both groups of patients received routine comprehensive treatment,on this basis,the observation group received Epalrestat Tablets.Both groups received continuous treatment for 12 weeks.Results Compared with those in the control group,the levels of glycated hemoglobin,fasting blood glucose,and 2-hour postprandial blood glucose in the observation group significantly reduced after treatment(P<0.05),the urine output significantly increased,and the levels of urine protein and urea nitrogen significantly decreased(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Epalrestat can improve the effect of blood glucose control and promote the recovery of renal function in patients with early type 2 diabetes nephropathy.